Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President
02 août 2021 08h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that current...
Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board
26 juil. 2021 16h18 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, July 26, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Mark Bach,...
Lumos Pharma to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021
22 juil. 2021 08h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, July 22, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will...
Lumos Pharma Announces Clinical Updates
20 juil. 2021 16h01 HE
|
Lumos Pharma, Inc.
OraGrowtH210 Trial in PGHD primary outcome 6-month data now anticipated in 2H2023; treatment period to be extended to 12 monthsOraGrowtH212 PK/PD Trial initiated in Q2 2021; treatment period to be...
Lumos Pharma Announces OraGrowtH212 Trial of LUM-201 in PGHD Is Open for Enrollment
28 juin 2021 08h00 HE
|
Lumos Pharma, Inc.
Single-Center Phase 2 Trial to Study the Pharmacokinetics/Pharmacodynamics (PK/PD) and Unique Pulsatile Mechanism of Action of LUM-201 at Two Dose Levels AUSTIN, Texas, June 28, 2021 (GLOBE...
Lumos Pharma to Participate in the Jefferies Virtual Healthcare Conference
19 mai 2021 09h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 19, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...
Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit
13 mai 2021 09h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...
Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
05 mai 2021 16h01 HE
|
Lumos Pharma, Inc.
Newly released PK/PD data from prior study in PGHD support endogenous LUM-201 MOA and use of Predictive Enrichment Markers (PEMs) to identify patients likely to respond to LUM-201 Data presented...
Lumos Pharma to Report First Quarter 2021 Financial Results and Host Conference Call on May 5, 2021
28 avr. 2021 09h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, April 28, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will...
Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Opinion Leader Webinar
27 avr. 2021 08h00 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, April 27, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that new...